Altre lingue Biogen Inc.

Azioni

BIIB

US09062X1037

Prodotti farmaceutici

Mercato chiuso - Nasdaq Altri mercati azionari 21:00:00 13/03/2026			Variaz. 5gg	Var. 1 gen.
181,55 ^USD	-1,81%		-1,80%	+3,16%

11/03	Biogen Inc. presenta ulteriori dati su salanersen e lancia il programma di studi clinici di Fase 3	CI
11/03	Biogen: i nuovi dati mostrano che il farmaco candidato Salanersen contro l'atrofia muscolare spinale rallenta la neurodegenerazione	MT

Altre lingue

12/03	Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Avantor, Inc. (AVTR), Baxter International Inc. (BAX), Biogen Inc. (BIIB), and CarMax, Inc. (KMX)
11/03	Biogen Inc. Presents Additional Salanersen Data and Debuts Phase 3 Clinical Trial Program
11/03	Biogen Says New Data Shows its Spinal Muscular Atrophy Drug Candidate Salanersen Slows Neurodegeneration
11/03	Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
11/03	Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
10/03	Biogen : to Participate in the Stifel 2026 Virtual CNS Forum
09/03	Global drugmakers rush to boost US presence as tariff threat looms
09/03	Spruce Biosciences Appoints Dale Hooks as Chief Commercial Officer, Effective March 9, 2026
06/03	Health Rounds: Protein related to Parkinson's linked to faster Alzheimer's progression in women
05/03	Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
05/03	Biogen Inc Announces to Present New Data and Updates from Its Spinal Muscle Atrophy Research Programs
04/03	The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
04/03	Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet Syndrome
04/03	NervGen Pharma Corp. Announces Executive Changes
03/03	Biogen : to Participate in the Leerink Global Healthcare Conference 2026
26/02	Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says
26/02	Xspray Pharma Announces CEO Changes, Effective June 1, 2026
24/02	Compañías que se deben tener muy en cuenta por técnico este martes en Wall Street
24/02	Valores destacados al cierre del mercado norteamericano
24/02	Biogen : to Participate in the TD Cowen 46th Annual Health Care Conference
23/02	Zura Bio Limited Announces Board Changes, Effective February 21, 2026
19/02	Eisai & Biogen Canada disagree with Canada's drug agency's Leqembi reimbursement rejection
19/02	Rückschlag für Alzheimer-Mittel Lecanemab von Eisai und Biogen
12/02	Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap…
11/02	Biogen Inc. Announces Board Changes